Speakers

Dr Spargo has PhD in organic chemistry from Cambridge University and has been involved in pharmaceutical research and development throughout an international career spanning 25 years, embracing all aspects of research and development, including working on a number of commercialized drugs. Prior to joining Verona Pharma as Vice President of Chemistry, Manufacturing and Controls (CMC), Dr Spargo held similar roles at Creabilis (UK/Italy) and at Novexel (France) where he played an important role in the $500 million acquisition by AstraZeneca in 2010.

Previously Dr Spargo was head of Chemical Process R&D for Pfizer in Europe responsible for the design, development and delivery of commercially viable synthetic routes to drug development candidates, supplying Active Pharmaceutical Ingredient (API) to meet the demands of toxicology, clinical and formulation development programmes and generating knowledge to underpin regulatory filings and transfer to commercial manufacturing. During his time at Pfizer, as well as his process chemistry responsibilities, Dr Spargo also lead Pharmaceutical Sciences development teams, embracing formulation and analytical activities, as well as leading a variety of multi-disciplinary human health development candidate project teams and being responsible for the company's Worldwide Pharmaceutical Sciences Veterinary Medicines portfolio.

Dr Spargo also spent a period at Scientific Update, providing consultancy and CMC management services to a wide range of pharmaceutical and biotech companies. He continues to provide independent consultancy services as time permits.

Presentation Title: Developing New Formulations for Respiratory Disease